Adverse effects have been poorly studied. The single systematic review of the literature did not report of the types and number of adverse events. In 2019, Health Canada stated that most autologous cell therapies have little evidence showing they work and can pose risks, such as cross-contamination between people if equipment is not sterilized properly or potentially dangerous immune reactions. Health Canada stopped Canadian clinics from offering these types of services with a donor-patient model. Health Canada later clarified that<unk>  treatments harvested from, and given back to, the same person (in a single procedure) was not covered by its initial guidance as the procedure falls under health care provider regulatory bodies (rather than Health Canada).
Platelet-rich plasma
Recombinant factor VIIa
Prothrombin complex concentrate
Protamine
Cryoprecipitate
Protamine sulfate
Fresh frozen plasma
Aminocaproic acid